Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1776-1782

  Abkevich, V ^a   Timms, K M ^a   Hennessy, B T ^b   Potter, J ^a   Carey, M S ^c   Meyer, L A ^d   Smith Mccune, K ^e   Broaddus, R ^f   Lu, K H ^f   Chen, J ^a   Tran, T V ^a   Williams, D ^a   Iliev, D ^a   Jammulapati, S ^a   Fitzgerald, L M ^a   Krivak, T ^g   Deloia, J A ^h   Gutin, A ^a   Mills, G B ^c   Lanchbury, J S ^a  

^a Myriad Genetic Laboratories   (United States)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

DNA double strand break repair; Homologous recombination deficiency; Loss of heterozygosity; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RAD51 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RECOMBINATION REPAIR; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE, TUMOR; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECOMBINATIONAL DNA REPAIR;

EID: 84869079205     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.451     Document Type: Article

References (26)

1. Beaudet al., Tsui LCA (1993) A suggested nomenclature for designating mutations. Hum Mutat 2: 245-248. (Pubitemid 23231498)
2. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL (2012) Telomeric allele imbalance indicated defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2: 366-375.
3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917. (Pubitemid 40559005)
4. Byler Dann R, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, Lanchbury JS, Krivak TC (2012) BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol 125: 677-682.
5. Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ (2011) Defective homologous recombination in human cancers. Cancer Treat Rev 38: 89-100.
6. Durkin AS, Reid YA (1998) Short tandem repeat loci utilized in human cell line identification. ATCC Connection 18: Numbers 2 & 3.
7. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111-1115. (Pubitemid 351317441)
8. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921. (Pubitemid 40559006)
9. Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MolGenMed 7: 60.
10. Gelmon KA, Thischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, nonrandomized study. Lancet Oncol 12: 852-861.
11. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, Smith McCune K, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients benefiting from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28: 3570-3576.
12. Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J (2010) BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 10: 654.
13. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Louise I, Kumar A (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43: 879-882.
14. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT (2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000-1004. (Pubitemid 38250946)
15. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Dei-ler H, Engel C, Müller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410-414.
16. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322.
17. Narayan G, Arias-Pulido J, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV (2003) Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2: 24.
18. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM (2011) Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29: 3008-3015.
19. O'Shaughnessy J, Osborne C, Pippin JE, Yoffe M, Patt D, Rocha C, Chou Koo I, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364: 205-214.
20. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69: 6381-6386.
21. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116-1120. (Pubitemid 351317449)
22. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinersdottir M, Valgeirsdottir S, Eyfjord JE (2009) Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 11: 404.
23. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME (2008) ''BRCAness'' syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26: 5530-5536.
24. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
25. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1. and BRCA2. Cell 208: 171-182. (Pubitemid 34161138)
26. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA (2005) Highresolution methylation analysis of the BRCA1 promoter in ovarian tumours. Cancer Genet Cytogenet 159: 114-122(Pubitemid 40719379)